Shattuck Labs to Present Topline Data from Phase 1 A/B Clinical Trial of SL-172154 in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and Higher-Risk Myelodysplastic Syndromes (HR-MDS) Patients at the American Society of Hematology (ASH) 2023 Annua
AUSTIN, Texas and DURHAM, N.C., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced the presentation of topline data from the dose escalation portion of its Phase 1 A/B clinical trial of SL-172154 as monotherapy and in combination with azacitidine (AZA) in primarily R/R AML and HR-MDS patients. These data will be featured in a poster presentation at the 65th ASH Annual Meeting, which is being held both virtually and in San Diego, CA from December 9-12, 2023.
- “Response rates are historically low for heavily pretreated relapsed/refractory AML and HR-MDS patients.
- Notably, preliminary data shows anti-leukemic effects detected in previously untreated TP53m-MDS and R/R AML patients.
- In bone marrow, abundant staining of SL-172154 was observed, along with a dose-dependent increase in phagocytic cells within mature myeloid immune cell compartments.
- Reduction in leukemic blasts was associated with an increase in mature myeloid and phagocytic cell phenotypes.